



October 25, 2016

**Samumed Successfully Completes a Phase II Androgenetic Alopecia (“AGA”) Biopsy Trial Studying Regeneration of Hair Follicles**

**San Diego, CA** – Samumed, LLC successfully completed a 135-day study of its topical compound, SM04554, on 49 male subjects with AGA analyzed by biopsy of the scalp prior to and post dosing. The safety and the efficacy results of this second Phase II Trial further support the safety and efficacy findings from the company’s prior trials. Moreover, the biopsy results support the program’s mechanism-of-action regarding new hair follicle regeneration.

As the Company previously reported, efficacy data from its first Phase II AGA trial showed statistically significant increases for both objective outcome measures: non-vellus hair count (a primary outcome measure) and hair density (a secondary outcome measure), using the pre-specified statistical model. Further, in that first Phase II AGA study, there were no serious adverse events observed in any treated patient, and the incidence of adverse events was similar between treatment and vehicle groups.

The Phase II AGA Biopsy study results will be presented at upcoming medical conferences.

**Media Inquiries**

Brunswick Group

David Seldin

+1 (202) 393-7337

[Samumed@brunswickgroup.com](mailto:Samumed@brunswickgroup.com)